| Name | Oxford Nanopore Technologies |
|---|---|
| Epic | ONT |
| Isin | GB00BP6S8Z30 |
| Index | UK250 UK350 |
| Industry | Pharmaceuticals & Biotechnology |
| Latest share price | 137.70p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £1,313.81 | Debt ratio | n/a |
| Shares in issue | 862.82 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | -25.25 |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -19 | 52-week high / low | 86.55p / 208.20p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Oxford Nanopore Technologies |
|---|---|
| Address | Gosling Building, Edmund Halley Road, Oxford Science Park, Oxford, United Kingdom, OX4 4DQ |
| Telephone | +44 (0)845 034 7900 |
| Website | https://nanoporetech.com/investors-update |
| Director | Position |
|---|---|
| Dr Gurdial (Gordon) Sanghera | CEO |
| Mr Nick Keher | CFO |
| Dr Guy Harmelin | Non-Executive Director |
| Mr Sarah Fortune | Non-Executive Director |
| Mr Adrian Nevil Hennah | Non-Executive Director |
| Mr Heather Preston | Non-Executive Director |
| Mr John O'Higgins | Non-Executive Director |
| Ms Kate Priestman | Non-Executive Director |
| Mr Duncan Tatton-Brown | Non-Executive Chairman |
| Mrs Wendy Becker | Senior Independent Director |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 32.91 | 30.04 | 23 |
| Investments and other non-current assets | 0.74 | 0.83 | 0.26 |
| Total non-current assets | 329.88 | 185.89 | 91.26 |
| Inventory / work in progress | 101.55 | 87.7 | 63.07 |
| Trade and other receivables | 61.47 | 62.9 | 54.8 |
| Cash and equivalents | 220.54 | 356.78 | 487.84 |
| Other current assets and asset held for resale | 63.62 | 130.62 | 144.9 |
| Total of all assets | 777.06 | 823.89 | 841.87 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 89.2 | 91.54 | 105.04 |
| Long term liabilities | 44.01 | 38.8 | 32.85 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 133.21 | 130.33 | 137.89 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 643.85 | 693.56 | 703.98 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 0.09 | 0.08 | 0.08 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -257.71 | -105.99 | -15.9 |
| Share premium account | 698.55 | 627.56 | 623.76 |
| Total equity | 643.85 | 693.56 | 703.98 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -168.61 | -98.48 | -164.53 |
| Pre-tax profit | -149.77 | -83.41 | -166 |